# QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia

> **NCT06456528** · PHASE2,PHASE3 · RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 235 (estimated)

## Conditions studied

- Cancer Treatment-Induced Thrombocytopenia

## Interventions

- **DRUG:** QL0911
- **DRUG:** QL0911 plus Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06456528
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-22
- **Primary completion:** 2026-07
- **Final completion:** 2026-12
- **Target enrollment:** 235 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06456528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06456528, "QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06456528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*